Advertisement
The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
TheBody.com/TheBodyPRO.com cover the XVIII International AIDS Conference (AIDS 2010)
  

Safety and Effectiveness of 1% Tenofovir Vaginal Microbicide Gel in South African Women: Results of the CAPRISA 004 Trial

July 20, 2010

Transcript (.pdf)

For more information on this session, including access to speaker presentations, please see the conference Programme-at-a-Glance.

An update of current state of microbicide development will be provided. Speakers will provide a state of microbicide development update, safety and efficacy data from CAPRISA 004 and implications of the CAPRISA 004 trial results for the microbicide and PrEP field.

Presentations in This Session:

Introduction
Co-Chairs: Tim Farley (Switzerland)
Department of Reproductive Health and Research (WHO)

Gita Ramjee (South Africa)
Head -- South Africa Medical Research Council's HIV Prevention Research Unit

The Caprisa 004 Result in Context
Sheena McCormack (United Kingdom)
Clinical Epidemiologist, MRC Clinical Trials Unit

Effectiveness of 1% Tenofovir Vaginal Microbicide Gel in South African Women: Results of the CAPRISA 004 Trial
Presented by Quarraisha Abdool Karim (South Africa)
Associate Professor of Clinical Epidemiology, Columbia University -- Southern African Fogarty AIDS

Do Systemic and Genital Tract Tenofovir Concentrations Predict HIV Seroconversion in the CAPRISA 004 Tenofovir Gel Trial?
Presented by Angela DM Kashuba (United States)
Associate Professor of Pharmacy at the University of North Carolina-Chapel Hill (UNC)

Safety of 1% Tenofovir Vaginal Microbicide Gel in South African Women: Results of the CAPRISA 004 Trial
Presented by Salim Abdool Karim (South Africa)
Chair, Department of Reproductive Health & Research WHO, Geneva
Director, Centre for the AIDS Programme of Research in South Africa (Caprisa), Durban
Director, HIV Prevention & Vaccine Research Unit, MRC
Pro Vice-Chancellor (Research), University of KwaZulu-Natal, Durban

Contextualising the CAPRISA 004 Trial Results in the HIV Prevention Field
Presented by Aaron Motsoaledi (South Africa)
Minister of Health

Conclusion

Safety and Effectiveness of 1% Tenofovir Vaginal Microbicide Gel in South African Women: Results of the CAPRISA 004 Trial (.mp3)


This information was reprinted from kff.org with permission from the Henry J. Kaiser Family Foundation. You can view all of Kaiser's coverage of the XVIII International AIDS Conference at http://www.kff.org/aids2010. © Henry J. Kaiser Family Foundation. All rights reserved.



  

This article was provided by Henry J. Kaiser Family Foundation. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
 
See Also
AIDS 2010: Study Finds Microbicide Containing HIV Drug Lowers Infection Risk in Women By 39%
More News and Research on Microbicides
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:



Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

AIDS 2010
Home
Choose a Topic:
Previous Conferences

Advertisement